By Dr. Priyom Bose, Ph.D.Dec 2 2022Reviewed by Danielle Ellis, B.Sc. Although most severe acute respiratory syndrome coronavirus 2 -infected individuals experience mild symptoms, some contract a severe infection that affects multiple organs in the acute phase. It is imperative to understand the disease mechanism to manage the infection effectively.
Viruses are involved with ubiquitin and ubiquitin-like modifiers via various mechanisms. For instance, some viruses encode a protein that causes alteration of substrate specificity to favor replication. The viral protein can effectively change the host’s ubiquitin and ubiquitin-like machinery. In addition, some viruses encode their own ubiquitinating or deubiquitinating enzymes.
About the study The ubiquitin gene profile helped identify the specific biological characteristics and clinical prognosis linked to these patients’ organs. Interestingly, the blood leukocytes of SARS-CoV-2 infected individuals indicated significant upregulation of the ubiquitin-associated pathway. The authors found a high negative correlation between levels of ubiquitin clusters and inflammatory reactions. This is a favorable outcome for COVID-19 patients, owing to enhanced immune infiltration and response.
We have summarized this news so that you can read it quickly. If you are interested in the news, you can read the full text here. Read more:
Health Health Latest News, Health Health Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Frontiers | Mucosal nanobody IgA as inhalable and affordable prophylactic and therapeutic treatment against SARS-CoV-2 and emerging variantsAnti-COVID antibody therapeutics have been developed but not widely used due to their high cost and escape of neutralization from the emerging variants. Here, we describe the development of VHH1.1, a nanobody IgA fusion molecular as an inhalable, affordable and less invasive prophylactic and therapeutic treatment against SARS-CoV-2 Omicron variants. VHH-IgA 1.1 recognizes a conserved epitope of SARS-CoV-2 spike protein Receptor Binding Domain (RBD) and potently neutralizes major global SARS-CoV-2 variants of concern (VOC) including the Omicron variant and its sub lineages BA.1.1, BA.2 and BA.2.12.1. The IgA fusion of VHH1.1 is also much more potent against Omicron variants as compared to its IgG Fc fusion demonstrating the importance of IgA mediated mucosal protection for Omicron infection. Intranasal administration of VHH-IgA1.1 prior to or after challenge conferred significant protection from severe respiratory disease in K18-ACE2 transgenic mice infected with SARS-CoV-2 VOC. More importantly, for cost-effective production, VHH-IgA1.1 produced in Pichia pastoris had comparable potency as mammalian produced antibody. Our study demonstrates that intranasal administration of VHH-IgA fusion protein produced affordably provides effective mucosal immunity against infection of SARS-CoV-2 including the emerging variants. FrontiersIn NatureComms 163k followers, not 1 comment, 10 minutes in? FrontiersIn NatureComms 163k followers, not 1 comment, 10 minutes in?
Source: medical_xpress - 🏆 101. / 51 Read more »
Researchers explore failed SARS-CoV-2 screening at hospital entrancesResearchers evaluated the failure rates of COVID-19 screening at hospital entrances for visitors, health professionals, and patients at the Yale New Haven Hospital in the US.
Source: NewsMedical - 🏆 19. / 71 Read more »
Risk factor assessment for the development of severe SARS-CoV-2 breakthrough infectionsresearchers evaluated the severity of breakthrough SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2) infections and the risk factors associated with severity among individuals vaccinated for coronavirus disease 2019 (COVID-19) in Sousse, Tunisia.
Source: NewsMedical - 🏆 19. / 71 Read more »